ACC 2022 | PACMAN AMI

Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous cap. Statins often reduce atherosclerosis progress, but the impact of PCSK 9 inhibitors (alirocumab) after acute coronary syndrome is scarcely known.

ACC 2022 | estudio PACMAN AMI

The aim of this study was to determine the effect of alirocumab using intracoronary imaging (IVUS, OCT, near-infrared spectroscopy (NIRS) in AMI patients. 

It included 300 patients mean age 58; 18% were women. There were STEMI (53%) and NSTEMI patients (47%) receiving culprit vessel PCI with no obstructive lesions in other arteries (20 toa 50% stenosis). 

Patients were randomized within 24 hrs. of PCI to receiving alirocumab 150 mg every 2 weeks in addition to 20 mg rosuvastatin vs placebo + rosuvastatin. Primary end point was changes in plaque volume by IVUS. Secondary end point was changes to the lipidic core by NIRS, and changes to fibrous cap thickness by OCT. 

There was plaque volume reduction in favor of the alirocumab (P<0.001). there were also significant differences in secondary end point for the intervention group. 

Read also: ACC 2022 | PROMPT-HF.

At one year, LDL values saw 50% reduction in the placebo group vs. 84% in the alirocumab group. As regards safety, the only significant adverse event in the intervention group was an allergic reaction. 

Conclusion

Among AMI patients, subcutaneous addition of alirocumab twice a week compared against placebo resulted in regression of atherosclerosis plaque 52 weeks after index event. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board ofSOLACI.org .

Reference: Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...